Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio Launches Early Access Program for Liquid Biopsy Platform

NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced the launch of an early access program for its LiquidBiopsy Rare Cell Isolation Platform.

The Mayo Clinic Cancer Center and the Norris Comprehensive Cancer Center, part of the Keck School of Medicine at the University of Southern California, are the first centers to participate in the program, which allows cancer research laboratories to have direct, on-site access to genomic material from highly purified cell populations for analysis. The LiquidBiopsy platform automates the identification and enrichment of rare tumor cells from standard patient blood draws, and delivers ultra-high sample purity for next-generation sequencing, PCR, expression analysis, fluorescent in situ hybridization, and immunohistochemistry.

The platform, Cynvenio added, can detect as few as one target cell per milliliter. Its technology has been available as a CLIA lab service to doctors and pharmaceutical firms since 2013, Cynvenio CEO André de Fusco said. "Our goal for the new LiquidBiopsy platform program is to enable those at the forefront of cancer research to unlock the complexities of tumor heterogeneity, concordance between sample types, and longitudinal patient monitoring," he said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.